OBJECTIVE: To observe the efficacy, toxicity and patients' qulity of life of cetuximab plus chemotherapy in the treatment of metastatic colorectal cancer. METHODS: From November 2006 to Februay 2009, eleven patients of advanced metastatic colorectal cancer with histologically confirmed diagnosis were treated with cetuximab in combination with FOLFIRI or FOLFOX regimen. Cetuximab was given at an initial dose of 400 mg/m2, followed by weekly infusions of 250 mg/m2. RESULTS: Of the 11 cases, the overall response rate (CR + PR) was 36.4%, the disease control rate (CR+PR+SD) was 90.9% (3 patients with CR, 1 patients with PR, 6 patients with SD, and 1 patient with PD). The main adverse effect was rash and the quality of life(QOL) of the patients improved. CONCLUSIONS: Cetuximab plus chemotherapy in the treatment of advanced metastatic colorectal cancer is proved to be active and tolerable. Except rash, it das not add the toxicity of chemotherapy and QOLs of patients are good.